- Home
- FUN vs RLAY Comparison
FUN vs RLAY Comparison
Compare FUN & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FUN | RLAY |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 1987 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FUN | RLAY |
|---|---|---|
| Price | $15.08 | $8.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | ★ $28.31 | $16.00 |
| AVG Volume (30 Days) | ★ 2.9M | 2.3M |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,137,510,000.00 | $8,355,000.00 |
| Revenue This Year | $14.07 | $20.47 |
| Revenue Next Year | $4.76 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 31.13 | N/A |
| 52 Week Low | $12.51 | $1.78 |
| 52 Week High | $49.77 | $9.04 |
Technical Indicators
Market Signals| Indicator | FUN | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 48.53 | 60.20 |
| Support Level | $13.00 | $8.25 |
| Resistance Level | $15.82 | $8.76 |
| Average True Range (ATR) | 0.67 | 0.45 |
| MACD | 0.25 | -0.03 |
| Stochastic Oscillator | 74.47 | 61.41 |
Price Performance
Historical ComparisonAbout FUN Cedar Fair L.P.
Six Flags Entertainment Corp is North America's regional amusement resort operator with approximately 27 amusement parks, around 15 separately gated water parks, and nine resort properties across the U.S., Canada, and Mexico. It provides coasters, themed rides, thrilling water parks, resorts, and a portfolio of beloved intellectual properties such as Looney Tunes, DC Comics, and PEANUTS.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).